Integragen (ALINT) - Total Liabilities

Latest as of June 2025: €3.26 Million EUR ≈ $3.82 Million USD

Based on the latest financial reports, Integragen (ALINT) has total liabilities worth €3.26 Million EUR (≈ $3.82 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Integragen (ALINT) equity growth momentum to track the company's year-over-year net asset growth rate.

Integragen - Total Liabilities Trend (2008–2024)

This chart illustrates how Integragen's total liabilities have evolved over time, based on quarterly financial data. See ALINT free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Integragen Competitors by Total Liabilities

The table below lists competitors of Integragen ranked by their total liabilities.

Company	Country	Total Liabilities
BioNeutra Global Corp V:BGA	Canada	CA$21.81 Million
TrustBIX Inc V:TBIX	Canada	CA$3.35 Million
Maven Income and Growth VCT 4 PLC LSE:MAV4	UK	GBX398.00K
Sarawak Cable Bhd KLSE:5170	Malaysia	RM466.66 Million
Satis Group S.A. WAR:STS	Poland	zł274.74 Million
Insplorion AB ST:INSP	Sweden	Skr3.60 Million
Rimo International Lestari Tbk PT JK:RIMO	Indonesia	Rp569.64 Billion

Liability Composition Analysis (2008–2024)

This chart breaks down Integragen's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Integragen worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.19	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	9.66	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.91	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Integragen's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Integragen (2008–2024)

The table below shows the annual total liabilities of Integragen from 2008 to 2024.

Year	Total Liabilities	Change
2024-12-31	€3.76 Million ≈ $4.39 Million	-37.24%
2023-12-31	€5.99 Million ≈ $7.00 Million	-12.21%
2022-12-31	€6.82 Million ≈ $7.98 Million	-8.03%
2021-12-31	€7.42 Million ≈ $8.67 Million	+11.55%
2020-12-31	€6.65 Million ≈ $7.77 Million	+56.88%
2019-12-31	€4.24 Million ≈ $4.96 Million	-26.77%
2018-12-31	€5.79 Million ≈ $6.77 Million	+22.68%
2017-12-31	€4.72 Million ≈ $5.52 Million	-25.18%
2016-12-31	€6.31 Million ≈ $7.37 Million	+10.91%
2015-12-31	€5.69 Million ≈ $6.65 Million	+5.16%
2014-12-31	€5.41 Million ≈ $6.32 Million	+6.20%
2013-12-31	€5.09 Million ≈ $5.95 Million	+10.30%
2012-12-31	€4.62 Million ≈ $5.40 Million	+19.14%
2011-12-31	€3.87 Million ≈ $4.53 Million	+27.16%
2010-12-31	€3.05 Million ≈ $3.56 Million	+4.81%
2009-12-31	€2.91 Million ≈ $3.40 Million	+38.75%
2008-12-31	€2.10 Million ≈ $2.45 Million	--

About Integragen

PA:ALINT France Biotechnology

Market Cap

$1.29 Million

€1.10 Million EUR

Market Cap Rank

#30499 Global

#574 in France

Share Price

€0.17

Change (1 day)

-2.06%

52-Week Range

€0.13 - €0.36

All Time High

€7.02